ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1279

Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1327

Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1361

Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1057

Impact of Osteoarthritis in Younger Adults

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1230

Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1309

Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1156

Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry

Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Abstract Number: 1317

Impairment of Memory in Axial Spondyloarthritis?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1178

Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1095

Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1375

Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1257

Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1159

Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions

Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Abstract Number: 1081

Improving Rheumatology Resource Utilization and Access to Specialty Care for Patients with Early Inflammatory Arthritis Through Enhanced Triage

Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Abstract Number: 1073

In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis

Health Services Research Poster II: Care Models and Innovation (1061–1082)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].